Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326060 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 354
- Enrollment target
NCT06326060 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 354 participants.
The verdict
NCT06326060, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 354 participants
- Enrollment target
Study Summary
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG NNC0519-0130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06326060
The ClinicalTrials.gov registry entry for NCT06326060 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06326060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06326060 about?
NCT06326060 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight". This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the st...
What is the current status of trial NCT06326060?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2024-03-18. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT06326060?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), NNC0519-0130 (DRUG).
Who is sponsoring clinical trial NCT06326060?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.